Arecor Therapeutics plc (AIM:AREC)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 27.37M |
| Revenue (ttm) | 5.06M |
| Net Income (ttm) | -8.10M |
| Shares Out | 37.76M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,109 |
| Average Volume | 11,930 |
| Open | 72.50 |
| Previous Close | 72.50 |
| Day's Range | 69.50 - 75.00 |
| 52-Week Range | 35.40 - 100.00 |
| Beta | -0.24 |
| RSI | 17.54 |
| Earnings Date | Apr 20, 2026 |
About Arecor Therapeutics
Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes;... [Read more]
Financial Performance
In 2024, Arecor Therapeutics's revenue was 5.05 million, an increase of 10.50% compared to the previous year's 4.57 million. Losses were -10.24 million, 19.7% more than in 2023.
Financial StatementsNews
Half Year 2025 Arecor Therapeutics PLC Earnings Presentation Transcript
Half Year 2025 Arecor Therapeutics PLC Earnings Presentation Transcript
AIM Market Roundup: Wishbone, Nativo Resources, Arecor Therapeutics
Wishbone, Nativo Resources, Arecor Therapeutics, Proteome Sciences and Bradda Head Lithium are today's top movers on London's AIM market
LGND: Ligand Pharmaceuticals Inks $11M Royalty Deal with Arecor
LGND: Ligand Pharmaceuticals Inks $11M Royalty Deal with Arecor
Arecor extends cash runway with US partnerships
Arecor has bolstered its balance sheet and sharpened its clinical focus, signing two US partnerships that will accelerate its drug pipeline.
Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing
AIM Market Roundup: The Revel Collective, Tanfield, Arecor
The Revel Collective, Tanfield, Arecor are today's top risers, while Pantheon Resources, Acuity RM take the biggest fall on London's AIM
Full Year 2024 Arecor Therapeutics PLC Earnings Presentation (Shareholder Q&A) Transcript
Full Year 2024 Arecor Therapeutics PLC Earnings Presentation (Shareholder Q&A) Transcript
Half Year 2024 Arecor Therapeutics PLC Earnings Presentation Transcript
Half Year 2024 Arecor Therapeutics PLC Earnings Presentation Transcript